Will Immunology Drugs Keep Driving AbbVie’s Top Line in 2026?

AbbVie (NYSE: ABBV) is entering 2026 with a clear message for investors: the company believes its newer immunology blockbusters—especially Skyrizi and Rinvoq—can keep revenue growing even as Humira continues to shrink under biosimilar pressure. In 2025, AbbVie delivered strong overall sales growth despite the well-known “patent cliff” headwind from Humira’s loss of exclusivity in the U.S. And for 2026, management has guided to a meaningfully higher revenue target, pointing to immunology as a major engine of that growth.

This article rewrites and expands the key ideas from the Zacks-style analysis (as syndicated on Nasdaq) and cross-checks the most important facts with AbbVie’s own reporting and major business coverage. We’ll break down what’s driving immunology growth, how AbbVie expects Skyrizi and Rinvoq to perform in 2026, what other business segments matter (like neuroscience and oncology), and what risks could still surprise investors.

Why 2026 Is a “Proof Year” for AbbVie’s Post-Humira Strategy

For years, the big question around AbbVie was simple: What happens when Humira declines? Humira was once one of the best-selling drugs in history, but biosimilar competition began hitting the U.S. market in early 2023. That shift forced AbbVie to execute a high-stakes transition—replacing a massive revenue stream with a new generation of products.

AbbVie’s plan has leaned heavily on two newer immunology medicines:

• Skyrizi (risankizumab), a biologic used across multiple immune-mediated diseases, including inflammatory bowel disease (IBD).
• Rinvoq (upadacitinib), an oral JAK inhibitor used in several immune-driven conditions, including atopic dermatitis, and competing in large indications like rheumatoid arthritis.

These products are designed to compete in many of the same “big markets” that made Humira so valuable—while also expanding into newer opportunities.

In the Nasdaq-syndicated Zacks piece, AbbVie is described as having posted roughly 8.5% sales growth in 2025 (at constant exchange rates), which is notable because it happened while Humira was still eroding. That’s the core point: AbbVie’s “replacement engines” are now large enough to offset a major decline and still push total revenue higher.

For 2026, the same analysis highlights AbbVie’s expectation that total revenue could reach around $67 billion, implying close to high single-digit to near double-digit growth versus 2025. The heavy lifting, again, is expected to come from immunology—primarily Skyrizi and Rinvoq.

The Big Number to Watch: Skyrizi + Rinvoq Could Exceed $31 Billion in 2026

If you only remember one forecast from AbbVie’s 2026 outlook, make it this: the company expects its two immunology stars to generate more than $31 billion combined in 2026, with Skyrizi around $21.5 billion and Rinvoq around $10.1 billion (as highlighted in the Nasdaq/Zacks analysis). Reuters also reported AbbVie’s expectation around the combined figure for 2026, underlining how central these two drugs are to the company’s revenue story.

That kind of scale matters for two reasons:

1. It reduces “Humira risk.” When your replacement products are that large, the company’s total revenue becomes less dependent on a single legacy blockbuster.
2. It can support multi-year growth. If Skyrizi and Rinvoq keep expanding in key indications, AbbVie can grow even if Humira becomes a smaller and smaller contributor.

Why Skyrizi Is a Growth Monster Right Now

Skyrizi has become one of the most important drugs in AbbVie’s entire portfolio, and its growth has been backed by strong performance across major disease areas—especially IBD categories like ulcerative colitis and Crohn’s disease. In AbbVie’s own reporting for full-year and fourth-quarter 2025, the company disclosed Skyrizi net revenues of about $5.006 billion (for the quarter figure referenced in the release), showing substantial year-over-year growth.

While quarterly numbers don’t automatically tell the full annual story by themselves, the trend is what matters: Skyrizi has been scaling fast, and AbbVie is guiding to an even bigger year in 2026. That guidance implies continued expansion in both volume and reach—more patients, more prescribers, and more market share where it competes.

Why Rinvoq Still Matters Even When Headlines Get Noisy

Rinvoq is the other half of AbbVie’s immunology “one-two punch.” It’s an oral therapy, which can be attractive in certain settings, and it competes in huge markets like rheumatoid arthritis and atopic dermatitis. AbbVie’s reported Rinvoq net revenues also showed strong growth in its 2025 results coverage.

Still, Rinvoq can attract more debate than Skyrizi because the JAK inhibitor category has faced close scrutiny. Even so, AbbVie continues to invest in data, label expansion, and competitive positioning. Reuters reported on clinical results where Rinvoq showed superiority over Humira in a head-to-head rheumatoid arthritis study—an example of the kind of evidence AbbVie uses to support physician confidence and market uptake.

In simple terms: Skyrizi provides powerful biologic momentum, while Rinvoq provides breadth across multiple immune conditions and a different treatment format (oral). Together, they form a diversified immunology growth platform—exactly what AbbVie needed after Humira.

Humira Isn’t Gone—But It’s No Longer the Main Character

Even in 2026, AbbVie still expects to earn revenue from Humira. The Nasdaq/Zacks analysis notes an expectation of around $2.9 billion from Humira sales in 2026 despite ongoing generic/biosimilar erosion. That figure shows Humira is becoming a much smaller slice of the pie—but still meaningful in absolute dollars.

This “tail revenue” can help AbbVie in two ways:

• Cash flow support: Even reduced Humira revenue can help fund R&D and shareholder returns.
• Transition cushion: As Skyrizi and Rinvoq ramp, Humira’s remaining sales reduce the risk of a sudden revenue gap.

But the bigger message is psychological and strategic: investors are watching whether AbbVie can prove it has moved from “Humira replacement mode” into “multi-franchise growth mode.” The 2026 guidance suggests management believes that shift is happening.

Neuroscience: The Quiet Diversifier That Could Add Real Fuel in 2026

While immunology gets most of the attention, AbbVie’s 2026 story isn’t only about Skyrizi and Rinvoq. The Nasdaq/Zacks analysis highlights AbbVie’s neuroscience franchise as a meaningful contributor, with an expectation of about $12.5 billion in neuroscience revenue for 2026—implying solid growth versus 2025.

Why does this matter? Because diversification reduces risk. If one segment slows, another can help keep the overall growth profile intact. AbbVie’s neuroscience lineup includes:

• Botox Therapeutic (distinct from aesthetics Botox), used in neurological conditions.
• Vraylar, used in mental health.
• Ubrelvy and Qulipta, oral migraine therapies.
• Vyalev, a Parkinson’s disease therapy mentioned as a newer entrant in the franchise mix.

These products help broaden AbbVie beyond immunology and build multiple “pillars” of revenue.

Pipeline Upside: Tavapadon as a Potential Next Step

Another important point raised in the Nasdaq/Zacks analysis is AbbVie’s work on a once-daily oral therapy for Parkinson’s disease called tavapadon, which it said was under FDA review at the time of writing and could potentially launch later in 2026 if approved. If that happens, AbbVie’s neuroscience footprint could expand further, adding another growth lever beyond immunology.

Note: Regulatory outcomes can change, and approvals depend on agency review. But strategically, it shows AbbVie’s playbook: build large anchor franchises, then keep layering in new launches to extend growth.

Oncology: A Near-Term Speed Bump, Especially for Imbruvica

Not every part of AbbVie’s business is expected to be a tailwind in 2026. The Nasdaq/Zacks analysis points to headwinds in oncology—particularly tied to Imbruvica, a drug AbbVie markets with Johnson & Johnson. The piece notes expectations for Imbruvica sales to decline further, with a forecast around $2.2 billion and a meaningful year-over-year drop.

The analysis links part of the pressure to pricing dynamics connected to the U.S. policy environment (including IRA-related effects referenced in the article). Even without diving deep into policy mechanics, the investor takeaway is clear: Imbruvica is not the growth driver it once was, and AbbVie is increasingly leaning on other oncology assets to balance that decline.

The same analysis highlights other oncology contributors that could cushion the impact, including:

• Venclexta (partnered with Roche) for certain blood cancers
• Epkinly (partnered with Genmab) for lymphoma
• Elahere for ovarian cancer
• Emrelis for lung cancer

In other words: oncology may be mixed in 2026, with legacy decline partly offset by newer products.

So, Will Immunology Really Drive AbbVie’s Top-Line Growth in 2026?

Based on the company’s guidance and the way recent trends have played out, immunology is positioned to be the main growth engine for AbbVie in 2026. The logic is straightforward:

• Skyrizi + Rinvoq are scaling rapidly and targeting enormous global patient populations.
• Humira’s decline is no longer a “company breaker” because AbbVie has built big enough alternatives.
• Other franchises like neuroscience add stability and can boost total growth even if one area slows.

Reuters’ reporting around AbbVie’s 2026 expectations reinforces the central role of the two immunology drugs, noting the company’s view that they can deliver a combined revenue figure in the low-$30 billions range in 2026. That’s not “nice to have”—that’s the core of the growth thesis.

Key Risks Investors Should Keep in Mind

Even a strong growth story has risks. Here are some of the most important ones to watch in 2026:

1) Competitive Pressure in Immunology

Immunology is a crowded, high-stakes space. Competitors continuously launch new data, new formulations, and new strategies to win market share—especially in IBD, psoriasis, and dermatitis. Skyrizi and Rinvoq can grow, but they must keep earning their place in treatment guidelines and real-world practice.

2) Safety and Label Dynamics

Rinvoq sits in a category that has faced close attention over time. Any changes in labeling, prescribing habits, or new comparative data could influence growth rates—positively or negatively.

3) Execution Risk in Neuroscience and Pipeline

AbbVie’s broader plan depends on new launches and steady performance across multiple franchises. Pipeline programs—like those under FDA review—can face delays or setbacks.

4) Oncology Declines Could Weigh More Than Expected

If declines in legacy oncology products accelerate faster than AbbVie anticipates, it could put pressure on total growth.

5) Market Expectations and Stock Volatility

Sometimes the biggest risk is expectations. Reuters noted AbbVie shares fell after the company’s outlook and product sales details, showing how quickly sentiment can shift even when guidance looks strong on the surface.

What to Monitor Quarter by Quarter in 2026

If you want a simple “dashboard” for AbbVie in 2026, focus on these items:

• Skyrizi sales growth rate (is it accelerating, steady, or slowing?)
• Rinvoq sales growth rate (especially in key indications like atopic dermatitis and IBD)
• Humira remaining revenue (is erosion stabilizing near the expected run-rate?)
• Neuroscience trajectory (Ubrelvy/Qulipta/Vraylar/Botox Therapeutic performance)
• Oncology offset (how much do newer oncology assets cushion Imbruvica?)

For original company updates, investors often use AbbVie’s investor relations releases and filings as a baseline source. Here is one reference point:

AbbVie Investor Relations: Full-Year and Fourth-Quarter 2025 Results

That type of primary source helps confirm what management is guiding and how the numbers are trending over time.

FAQ: AbbVie, Skyrizi, Rinvoq, and the 2026 Growth Outlook

1) What is AbbVie’s main growth driver in 2026?

AbbVie expects its newer immunology drugs—especially Skyrizi and Rinvoq—to be the primary drivers of 2026 revenue growth.

2) How much revenue could Skyrizi and Rinvoq generate in 2026?

The Nasdaq/Zacks analysis projects combined sales of over $31 billion in 2026, with Skyrizi around $21.5 billion and Rinvoq around $10.1 billion. Reuters also reported AbbVie’s expectation around the combined figure.

3) Is Humira still important to AbbVie in 2026?

Humira is much smaller than it once was, but it still contributes revenue. The Nasdaq/Zacks analysis cites an expectation of about $2.9 billion in Humira sales in 2026 despite ongoing erosion.

4) What is AbbVie’s total revenue target for 2026?

The Nasdaq/Zacks analysis notes AbbVie’s guidance implying a top line around $67 billion for 2026.

5) Besides immunology, what other segment could boost AbbVie in 2026?

Neuroscience is highlighted as an additional growth contributor, with the Nasdaq/Zacks analysis pointing to an expectation of about $12.5 billion from neuroscience in 2026.

6) What’s the main weak spot in AbbVie’s 2026 outlook?

Oncology faces near-term headwinds, especially due to the continued decline of Imbruvica, which the Nasdaq/Zacks analysis expects to fall further in 2026.

Conclusion: Immunology Looks Set to Lead—But Execution Still Matters

AbbVie’s 2026 narrative is increasingly a story of immunology leadership rather than Humira dependence. The company is projecting that Skyrizi and Rinvoq will not only offset Humira’s erosion but also push total revenue meaningfully higher. If AbbVie delivers on its expectations—particularly the combined $31B+ immunology forecast—2026 could further validate one of the biggest pharma transitions of the decade: moving from a single mega-blockbuster era into a multi-franchise growth model.

At the same time, investors shouldn’t ignore the moving parts: competitive dynamics in immunology, evolving product mix in neuroscience, and oncology pressure from older assets. The good news is that AbbVie is no longer relying on just one lever. The company has built a broader platform—so success in 2026 will likely come from consistent execution across several franchises, with immunology at the center of the stage.

#AbbVie #Skyrizi #Rinvoq #PharmaStocks #SlimScan #GrowthStocks #CANSLIM